RAP-219 not checked

Rapport Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
4 active
6 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.”In the company’s words, NCT07219407 on ClinicalTrials.gov
Tested for
Epilepsy (4 trials), Focal Seizure (3 trials), Focal Epilepsy (3 trials), Refractory Focal Epilepsy, Seizure, Focal Onset Seizure
Main trialPhase 3
“This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure frequency.”In the company’s words, NCT07563881 on ClinicalTrials.gov

Other drugs for Epilepsy

All 32 drugs for Epilepsy

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jul 2029 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
Phase 3Recruiting Jul 2029 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
Phase 2Recruiting 3 Feb 2028 A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Phase 1Recruiting Jun 2027 Study Designed to Evaluate the Safety, Tolerability, and PK of RAP-219 Formulated as an Long Acting Injectable.
Phase 2Completed 26 Sep 2025 Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
Phase 2Completed 5 Aug 2026 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow RAP-219

Following is part of Solo: you see every change to RAP-219 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in